Narjust Florez, Co Director Young Lung Cancer Program at Dana-Farber Cancer Institute, shared on LinkedIn:
“How do we optimize lung cancer treatment sequencing in 2026?
Here is a quick breakdown of our panel consensus thoracic oncologists on NSCLC, SCLC, and emerging biomarkers.
Swipe through for the highlights.
Alongside an incredible group of co-authors.”
Title: Current Challenges and Emerging Therapeutic Strategies in Lung Cancer Care: Insights From Bridging the Gaps 2025
Authors: Narjust Florez, Sandip Pravin Patel, Ravi Salgia, Jacob Sands, Erin L. Schenk, Elaine Shum, Mihaela Aldea, Christine M. Bestvina, Jessica Donington, Christine A. Garcia, Jorge Nieva, David R. Gandara, Balazs Halmos, Fred R. Hirsch, Xiuning Le, Percy Lee, Jyoti Malhotra, Tejas Patil, Solange Peters, Jonathan Wesley Riess, Julia Rotow, Fawzi Abu Rous, Joshua Sabari, Triparna Sen, Eric K. Singhi, Ana I. Velázquez, Heather A. Wakelee, Edward S. Kim.
Read the full article.
You might be interested in:
Unresectable Stage III NSCLC: PACIFIC Remains the Backbone as Precision Strategies Reshape Care
